
Consider IPD protection against what matters1
When it comes to protecting your pediatric patients against IPD, the number of serotypes in a vaccine is just one aspect to consider1,2
Although more than 100 S. pneumoniae serotypes have been documented, certain key disease-causing serotypes are more prevalent than others and are associated with higher morbidity and mortality rates.1-4,a
In a pooled analysis from 2018-2022,
~1 in 4 cases
of IPD in children younger than 5 years old were caused by serotypes:1,a
These 3 serotypes can cause significant IPD-related morbidity in children and are also associated with varying degrees of antimicrobial resistance.3,5
Despite being included in PCVs for over 10 years, Serotype 3 continues to be a leading cause of pediatric IPD in children under 5 years of age.1,6,a
aIn a pooled analysis of national-level CDC ABC surveillance data from 2018–2022, the top 6 IPD-causing serotypes in children under 5 years of age were 15C, 3, 19F, 22F, 33F, and 23B. Serotypes 15C and 23B are not included in any recommended pediatric PCV in the US.1,7,8
ABC, Active Bacterial Core; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.
Get details on first year of life
See immunogenicity data
Learn about special populations
View safety & tolerability data
References:
- Visualization – based on 2018-2022 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance (ABCs). Centers for Disease Control and Prevention. Updated July 22, 2024. Accessed August 27, 2024. https://data.cdc.gov/d/qvzb-qs6p/visualization
- Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 9, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
- Hu T, Weiss T, Owusu-Edusei K, Petigara T. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States. J Med Econ. 2020;23(12):1653-1660. doi:10.1080/13696998.2020.18 40216
- Yildirim M, Keskinocak P, Hinderstein S, et al. A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease. Vaccine. 2025;47:126692. doi:10.1016/j.vaccine.2024.126692
- Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26(4):512.e1-512.e10. doi:10.1016/j.cmi.2019.09.008
- Prevnar 13. Prescribing Information. Pfizer; 2019.
- Prevnar 20. Prescribing Information. Pfizer; 2023.
- Pneumococcal Vaccine Recommendations. Centers for Disease Control and Prevention. Last reviewed October 26, 2024. Accessed November 18, 2024. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
- Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States 2025. Updated November 21, 2024. Accessed December 2, 2024. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-childcombined-schedule.pdf
- Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, Annex 3, TRS No 977. World Health Organization. October 19, 2013. Accessed January 30, 2025 https://www.who.int/publications/m/item/pneumococcal-conjugate-vaccines-annex3-trs-977
- Annex 9. Guidelines on clinical evaluation of vaccines: regulatory expectations. World Health Organization. Last reviewed October 21, 2020. Accessed May 28, 2024. https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9